Copyright
©The Author(s) 2023.
World J Clin Cases. Sep 16, 2023; 11(26): 6083-6090
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6083
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6083
Table 3 Comparison of the adverse reactions between the two study groups, n (%)
| Group | Level | Skin reactions on hands and feet | Peripheral neuritis | Vomiting | Diarrhea | Abnormal liver function | Leukopenia |
| FLOT group (n = 42) | Level 0 to 2; Level 3 & 4 | 41 (97.62); 1 (2.38) | 41 (97.62); 1 (2.38) | 38 (90.48); 4 (9.52) | 39 (92.86); 3 (7.14) | 40 (95.24); 2 (4.76) | 25 (59.52); 17 (40.48) |
| SOX group (n = 42) | Level 0 to 2; Level 3 & 4 | 34 (80.95); 8 (19.05)a | 42 (100.00); 0 (0.00) | 40 (95.24); 2 (4.76) | 40 (95.24); 2 (4.76) | 41 (97.62); 1 (2.38) | 35 (83.33); 7 (16.67)a |
- Citation: Zheng L, Gan LH, Yao L, Li B, Huang YQ, Zhang FB, Kuang MQ, Fang N. Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer. World J Clin Cases 2023; 11(26): 6083-6090
- URL: https://www.wjgnet.com/2307-8960/full/v11/i26/6083.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i26.6083